Literature DB >> 2195457

[Enzymatic resistance to cefotaxime in 56 strains of Klebsiella spp., Escherichia coli and Salmonella spp. at a Tunisian hospital (1984-1988)].

A Ben Hassen1, G Fournier, A Kechrid, C Fendri, S Ben Redjeb, A Philippon.   

Abstract

The enzymatic and plasmid-encoded resistance towards oxyimino-beta-lactams has been recently reported as related to the production of an extended-spectrum beta-lactamase (e.g. SHV-2, CTX-1 or TEM-3), in particular in our hospital since 1984. The prevalence of that resistance has been examined from January 1984 to December 1988 in function of specimen, unit and type of enzyme among 8,421 isolates of Klebsiella spp., E. coli, Salmonella spp. Each isolate showing a diameter of inhibition zone size inferior or equal to 25 mm for cefotaxime, the double disk synergy test was performed between a disk of amoxicillin and a clavulanic acid disk of cefotaxime, ceftriaxone, ceftazidime and aztreonam. In case of synergy, sonicated extracts have been prepared and examined by isoelectrofocusing with the detection of beta-lactamase activity by ceftriaxone and nitrocefin. 56 isolates (K. pneumoniae, K. oxytoca, E. coli, S. wien, S. typhimurium scored positive including 27 in pediatrics, 18 in surgery, and 8 in medicine. 41% of isolates have been obtained from blood cultures and 26.8% from urines. A majority of isolates (49/56) produced the SHV-2 type, but other types mediating the resistance phenotype CTX have been individualized initially by their isoelectric points e.g. 5.4 (TEM-20 in K. pneumoniae in July 1986), 6.4 (TEM-21 in E. coli, 1 K. pneumoniae in July 1988). The prevalence of resistance to cefotaxime from 1984 to 1988 has increased (from 0.3 to 1.4%), the highest rate being observed in pediatrics (5.6% in 1984 and 22.1% in 1988).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195457

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  4 in total

1.  Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase.

Authors:  G L French; K P Shannon; N Simmons
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

2.  beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa.

Authors:  J D Pitout; K S Thomson; N D Hanson; A F Ehrhardt; E S Moland; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey.

Authors:  Seok Hoon Jeong; Il Kwon Bae; Jung Hun Lee; Seung Ghyu Sohn; Geun Ho Kang; Ghil Ja Jeon; Young Ho Kim; Byeong Chul Jeong; Sang Hee Lee
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

4.  Epidemiology of resistance and phenotypic characterization of carbapenem resistance mechanisms in Klebsiella pneumoniae isolates at Sahloul University Hospital-Sousse, Tunisia.

Authors:  Aziza Messaoudi; Wejdène Mansour; Nedia Jaidane; Chrifa Chaouch; Noureddine Boujaâfar; Olfa Bouallègue
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.